Login
$XFOR
$2.84 +$0.01 (0.35%) After hours

$XFOR 8-K/A SEC Filings

Filed On Filing
13 May 2026 8-K/A: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of this Second Amended and Restated 2017 Equity Incentive Plan (the “Plan”) of X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Compa...

26 Jan 2022 8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

X4 Pharmaceuticals, Inc. (the “Company”) intends to share with investors the amount of cash, cash equivalents and restricted cash it had on hand as of December 31, 2021, as well as the principal amount of outstanding debt, its number of ...

18 Oct 2019 8-K/A: Departure/Election of Directors or Officers; Compensation

As reported in the Original Filing, on September 18, 2019, the Board of Directors (the “Board”) of the Company appointed William E. Aliski to the Board as a Class II director. Committee assignments for Mr. Aliski were not determined as o...

17 May 2019 8-K/A: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

13 May 2019 8-K/A: Financial Statements and Exhibits

This License Agreement (this “Agreement”) is executed as of July 10, 2014 (the “Effective Date”) by and between Genzyme Corp., a corporation having an address at 500 Kendall Street, Cambridge, MA 02142 (“Genzyme” or “Licensor”) and X4 Ph...

03 Apr 2019 8-K/A: Financial Statements and Exhibits

To the Board of Directors and Stockholders of X4 Therapeutics, Inc. (formerly known as X4 Pharmaceuticals, Inc.)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support